A new paediatric formulation of valaciclovir: development and bioequivalence assessment-Reference-Cited by-同舟云学术

A new paediatric formulation of valaciclovir: development and bioequivalence assessment

Published:2016-05-09 Issue:10 Volume:101 Page:971-972
ISSN:0003-9888
Container-title:Archives of Disease in Childhood
language:en
Short-container-title:Arch Dis Child

Author:

Bastiaans Diane E T,Bartels-Wilmer Carli M,Colbers Angela P H,Heijens Claudia A W,Velthoven-Graafland Kirsten,Smeets Oscar S N M,Vink Nicole,Harbers Veroniek E M,Warris Adilia^ORCID,Burger David M

Funder

ZonMw

Publisher

BMJ

Subject

Pediatrics, Perinatology, and Child Health

Reference4 articles.

1. Stability of valacyclovir hydrochloride in extemporaneously prepared oral liquids;Fish;Am J Health Syst Pharm,1999

2. Pharmacokinetics and safety of valaciclovir in children with Epstein-Barr virus illness;Simon;Drugs R D,2002

3. European Medicines Agency. Reflection paper: Formulations of choice for the paediatric population. EMEA/CHMP/PEG/194810/2005, London, 28 July 2006.

4. European Medicines Agency. Guideline on the investigation of bioequivalence. CPMP/EWP/QWP/1401/98 Rev. 1/Corr, London, 20 January 2010.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pediatric drug delivery challenges: Enhancing compliance through age-appropriate formulations and safety measures;Journal of Drug Delivery Science and Technology;2024-06

2. Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update;Pharmaceutics;2022-05-10

3. In vivo and in vitro palatability testing of a new paediatric formulation of valaciclovir;British Journal of Clinical Pharmacology;2017-09-20